Article citationsMore>>

Singh, R., Kaiser, P., Srivastava, S., Ehlers, J., Silva, F., Bedi, R., et al. (2015) A Single-Arm, Investigator-Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects with Exudative Age-Related Macular Degeneration Previously Treated with Ranibizumab or Bevacizumab (ASSESS Study): 12-Month Analysis. Clinical Ophthalmology, 9, 1759-1766.
https://doi.org/10.2147/opth.s87043

has been cited by the following article:

• TITLE: Comparison of Aflibercept and Ranibizumab on Functional and Morphological Outcome in Exudative Age-Related Macular Degeneration

  AUTHORS: Xue Wang, Chaofeng Yu, Jingjing Ding

  KEYWORDS: Ranibizumab, Aflibercept, Age-Related Macular Degeneration

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.2, February 20, 2025

  ABSTRACT: Background: Exudative, or “wet” age-related macular degeneration (wAMD), characterized by choroidal neovascularization and consequent accumulation of subretinal fluid, is the leading cause of visual loss in elderly patients in Western countries. Objective: To compare the effectiveness of aflibercept vs. ranibizumab for treatment-naive wAMD patients in the real world. Methods: PubMed, Web of Science and Cochrane Library were searched to compare aflibercept with ranibizumab. 21 studies with a total of 13,004 eyes were selected and assessed in this meta-analysis. Results: Compared to ranibizumab, aflibercept was more effective in improving best-corrected visual acuity (BCVA) at 12 months (WMD: −0.04; 95% CI: −0.07 to 0.00; p = 0.04). At 3 months, aflibercept was superior to ranibizumab in reducing central retinal thickness in patients with worse baseline BCVA (WMD: −36.19; 95% CI: −71.47 to −0.92; p = 0.04), reducing subfoveal choroidal thickness in patients with better baseline BCVA (WMD: −12.67; 95% CI: −21.33 to −4.02; p = 0.004), reducing height of subfoveal pigment epithelial detachment (WMD: −43.88; 95% CI: −73.88 to −13.87; p = 0.004) and improving the incidence of “dry macula” occurrence (OR: 2.26; 95% CI: 1.33 to 3.82; p = 0.003). Conclusions: Compared with ranibizumab, aflibercept showed better efficacy in improving morphological changes at 3 months and visual acuity at 12 months post treatment initiation in community clinical setting.